18th Jan 2021 18:26
(Alliance News) - GlaxoSmithKline PLC on Monday said results from the Garnet study showed durable responses across tumour types.
Glaxo said the study results showed a 38.7% objective response rate in patients with deficient mismatch repair advanced solid cancers who received the dostarlimab monoclonal antibody. Additionally, after a median follow-up of 12.4 months, the median duration of response had not yet been reached and responses were durable across tumour types.
The ongoing phase I Garnet trial is evaluating dostarlimab as monotherapy in patients with advanced solid tumours.
Senior Vice President and Head of Oncology R&D Axel Hoos said: "We are committed to finding new approaches to improve outcomes for patients with difficult to treat cancers who have limited treatment options today. These new results from the ongoing GARNET study demonstrate the potential for dostarlimab to help a broad range of patients with solid tumours that have a deficiency in DNA mismatch repair."
The stock closed down 0.9% at 1,400.74 pence on Monday in London.
By Arvind Bhunjun; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline